---
schema_version: "secwatch.filing_event.v1"
accession: "0001736730-26-000021"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:13:57.558090+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# CAMP4 appoints Michael MacLean to Board, effective April 1, 2026

## Summary
- Michael MacLean, former CFO of Avidity Biosciences, joins as Class III director; board expands to 9 members.
- MacLean appointed to Audit and Compensation Committees; will receive standard director compensation.
- Board amended non-employee director compensation policy: new directors granted options for 56,000 shares vesting over 3 years.
- MacLean brings over 35 years of financial leadership in biotech, including roles at Avidity, Akcea, PureTech, and Biogen.

## SEC filing metadata
- accession: 0001736730-26-000021
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000021/0001736730-26-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000021/camp-20260318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001736730-26-000021
- JSON: https://secwatch.observer/filing/0001736730-26-000021.json
- Plain text: https://secwatch.observer/filing/0001736730-26-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.